Stock Titan Trading tools for traders and investors.

-

10:42:48 PM

Last MGNX Stock Market News

MGNX - Macrogenics Inc

02/26/21 7:30 AM

Nasdaq : MGNX

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in

RHEA-AI

neutral

02/25/21 4:01 PM

Nasdaq : MGNX

MacroGenics Provides Update on Corporate Progress and 2020 Financial Results

MARGENZA(TM) approved in December 2020; commercial launch expected March 2021 July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab Multiple clinical updates across portfolio anticipated in 2021 Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., Feb.

RHEA-AI

neutral

02/18/21 4:30 PM

Nasdaq : MGNX

MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

RHEA-AI

neutral

02/11/21 4:30 PM

Nasdaq : MGNX

MacroGenics Names Federica O'Brien to its Board of Directors

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica "Freddi" O'Brien,

RHEA-AI

neutral

02/11/21 7:30 AM

Nasdaq : MGNX

MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been achieved

RHEA-AI

very positive

02/08/21 7:30 AM

Nasdaq : MGNX

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in

RHEA-AI

neutral

01/25/21 7:30 AM

Nasdaq : MGNX

MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA(TM) in JAMA Oncology

Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin(R) ( trastuzumab), both with chemotherapy In the U.S., MARGENZA is approved, in combination with chemotherapy, for the treatment of adult

RHEA-AI

neutral

01/11/21 8:45 AM

Nasdaq : MGNX

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate

RHEA-AI

neutral

12/22/20 11:35 AM

Nasdaq : MGNX

MacroGenics Announces MGD019 Publication in Cell Reports Medicine

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based

RHEA-AI

positive

12/18/20 7:30 AM

Nasdaq : MGNX

MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART(R) Molecule

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license

RHEA-AI

neutral